<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303156</url>
  </required_header>
  <id_info>
    <org_study_id>8591-026</org_study_id>
    <secondary_id>2020-000153-27</secondary_id>
    <secondary_id>MK-8591-026</secondary_id>
    <nct_id>NCT04303156</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir (MK-8591) in Subjects With Severe Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the general tolerability and pharmacokinetics (PK) of a single 60 mg&#xD;
      dose of MK-8591 (Islatravir) in participants with severe renal insufficiency, compared to&#xD;
      participants in good health.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Actual">October 19, 2020</completion_date>
  <primary_completion_date type="Actual">October 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL)</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Participants were treated with islatravir (ISL), and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Concentration (Tmax) of Plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Tmax of plasma ISL was expressed as a median.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of Plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/F) of Plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)</measure>
    <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL, and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-last of ISL-TP in PBMC</measure>
    <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ISL-TP in PBMC</measure>
    <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ISL-TP in PBMC</measure>
    <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The Tmax of ISL-TP was expressed as a median.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Participants were treated with ISL and peripheral blood samples were collected at 24 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC</measure>
    <time_frame>168 hours post-dose</time_frame>
    <description>Participants were treated with ISL and peripheral blood samples were collected at 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC</measure>
    <time_frame>672 hours post-dose</time_frame>
    <description>Participants were treated with ISL and peripheral blood samples were collected at 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of ISL-TP in PBMC</measure>
    <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
    <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The t1/2 of plasma ISL was expressed as a geometric mean. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Adverse Event (AE)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued From the Study Due to an AE</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Human Immunodeficiency Virus (HIV) Infection</condition>
  <arm_group>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe renal impairment received a single oral dose of 60 mg MK-8591 (Islatravir) administered in capsule form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Islatravir</intervention_name>
    <description>Single oral dose of 60 mg Islatravir administered in capsule form</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <other_name>MK-8591</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy participants must have the following:&#xD;
&#xD;
          -  Is in good health&#xD;
&#xD;
          -  Has a body mass index (BMI) ≥18.5 and ≤40 kg/m2.&#xD;
&#xD;
          -  Female is not pregnant or breastfeeding, and is not one of the following: a woman of&#xD;
             childbearing potential (WOCBP); if a WOCBP, is using an acceptable contraceptive&#xD;
             method, or is abstinent from heterosexual intercourse as their preferred and usual&#xD;
             lifestyle; a WOCBP must have a negative highly sensitive pregnancy test within 24&#xD;
             hours before the first dose of study intervention&#xD;
&#xD;
        Renally impaired participants must have the following:&#xD;
&#xD;
          -  With the exception of renal impairment, is in generally good health&#xD;
&#xD;
          -  Has a BMI ≥ 18.5 and ≤ 40 kg/m2&#xD;
&#xD;
          -  Female is not pregnant or breastfeeding, and is not one of the following: a woman of&#xD;
             childbearing potential (WOCBP); if a WOCBP, is using an acceptable contraceptive&#xD;
             method, or is abstinent from heterosexual intercourse as their preferred and usual&#xD;
             lifestyle; a WOCBP must have a negative highly sensitive pregnancy test within 24&#xD;
             hours before the first dose of study intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy participants must have the following:&#xD;
&#xD;
          -  Has a history of clinically significant endocrine, gastrointestinal, cardiovascular,&#xD;
             hematological, hepatic, immunological, renal, respiratory, genitourinary, or major&#xD;
             neurological (including stroke and chronic seizures) abnormalities or diseases.&#xD;
&#xD;
          -  Is mentally or legally incapacitated, has significant emotional problems&#xD;
&#xD;
          -  Has known hypersensitivity to the active substance or any of the excipients of the&#xD;
             study drug&#xD;
&#xD;
          -  Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex&#xD;
             allergy), or has had an anaphylactic reaction or significant intolerability (i.e.&#xD;
             systemic allergic reaction) to prescription or non-prescription drugs or food.&#xD;
&#xD;
          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.&#xD;
&#xD;
          -  Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within prior&#xD;
             4 weeks&#xD;
&#xD;
          -  Is taking medications to treat chronic medical conditions and/or conditions associated&#xD;
             with renal disease&#xD;
&#xD;
          -  Has participated in another investigational study within prior 4 weeks&#xD;
&#xD;
        Other exclusions for healthy participants:&#xD;
&#xD;
          -  Does not agree to follow the smoking restrictions&#xD;
&#xD;
          -  Consumes greater than 1 glass for women, or 2 glasses for men of alcoholic beverages&#xD;
             per day&#xD;
&#xD;
          -  Consumes excessive amounts,of caffeinated beverages per day.&#xD;
&#xD;
          -  Is a regular user of cannabis, any illicit drugs or has a history of drug (including&#xD;
             alcohol) abuse within approximately prior 3 months.&#xD;
&#xD;
        Renally impaired participants must have the following:&#xD;
&#xD;
          -  Has a history or presence of renal artery stenosis.&#xD;
&#xD;
          -  Has had a renal transplant or nephrectomy.&#xD;
&#xD;
          -  Has rapidly fluctuating renal function as determined by historical measurements.&#xD;
&#xD;
          -  Has known hypersensitivity to the active substance or any of the excipients of the&#xD;
             study drug.&#xD;
&#xD;
          -  Has a history of cancer (malignancy).&#xD;
&#xD;
          -  Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex&#xD;
             allergy), or has had an anaphylactic reaction or significant intolerability (i.e.&#xD;
             systemic allergic reaction) to prescription or non-prescription drugs or food.&#xD;
&#xD;
          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies or human&#xD;
             immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4&#xD;
             weeks prior to the prestudy (screening) visit.&#xD;
&#xD;
          -  Is taking medications to treat chronic medical conditions and/or conditions associated&#xD;
             with renal disease and has not been on a stable regimen for at least 1 month and/or is&#xD;
             unable to withhold the use of the medication(s) within 4 hours prior to and 8 hours&#xD;
             after administration of the study drug.&#xD;
&#xD;
          -  Has participated in another investigational study within 4 weeks (or 5 half-lives,&#xD;
             whichever is greater) prior to the prestudy (screening) visit.&#xD;
&#xD;
        Other exclusions for renally impaired participants&#xD;
&#xD;
          -  Does not agree to follow the smoking restrictions.&#xD;
&#xD;
          -  Consumes greater than 1 glass for women, or 2 glasses for men of alcoholic beverages&#xD;
             per day.&#xD;
&#xD;
          -  Consumes excessive amounts of caffeinated beverages per day.&#xD;
&#xD;
          -  Is a regular user of cannabis, any illicit drugs or has a history of drug (including&#xD;
             alcohol) abuse within approximately 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami ( Site 0001)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Research Organisation GmbH ( Site 0003)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <results_first_submitted>September 29, 2021</results_first_submitted>
  <results_first_submitted_qc>September 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2021</results_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Islatravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT04303156/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male and females with severe renal impairment between the ages of 18 and 75 years old (inclusive), and healthy matched controls were enrolled in this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Severe Renal Impairment</title>
          <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
        </group>
        <group group_id="P2">
          <title>Healthy</title>
          <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Severe Renal Impairment</title>
          <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
        </group>
        <group group_id="B2">
          <title>Healthy</title>
          <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="12.9"/>
                    <measurement group_id="B2" value="58.8" spread="5.5"/>
                    <measurement group_id="B3" value="58.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL)</title>
        <description>Participants were treated with islatravir (ISL), and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL)</title>
          <description>Participants were treated with islatravir (ISL), and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>hr*μM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="11.8" upper_limit="17.6"/>
                    <measurement group_id="O2" value="6.54" lower_limit="4.77" upper_limit="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric mean ratio (GMR)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>2.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.68</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Plasma ISL</title>
        <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Plasma ISL</title>
          <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>hr*μM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="9.17" upper_limit="13.1"/>
                    <measurement group_id="O2" value="5.68" lower_limit="4.06" upper_limit="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>1.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Plasma ISL</title>
        <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Plasma ISL</title>
          <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>μM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="1.06" upper_limit="1.42"/>
                    <measurement group_id="O2" value="1.19" lower_limit="0.699" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Concentration (Tmax) of Plasma ISL</title>
        <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Tmax of plasma ISL was expressed as a median.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Concentration (Tmax) of Plasma ISL</title>
          <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Tmax of plasma ISL was expressed as a median.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.5" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2) of Plasma ISL</title>
        <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) of Plasma ISL</title>
          <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" spread="7.7"/>
                    <measurement group_id="O2" value="72.0" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance (CL/F) of Plasma ISL</title>
        <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) of Plasma ISL</title>
          <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="11.6" upper_limit="17.4"/>
                    <measurement group_id="O2" value="31.3" lower_limit="22.8" upper_limit="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>0.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vz/F) of Plasma ISL</title>
        <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) of Plasma ISL</title>
          <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2610" lower_limit="2170" upper_limit="3140"/>
                    <measurement group_id="O2" value="3250" lower_limit="2100" upper_limit="5030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>0.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)</title>
        <description>Participants were treated with ISL, and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)</title>
          <description>Participants were treated with ISL, and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>hr*pmol/10^6 cells</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5810" lower_limit="3890" upper_limit="8700"/>
                    <measurement group_id="O2" value="3920" lower_limit="2830" upper_limit="5420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>1.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-last of ISL-TP in PBMC</title>
        <description>Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-last of ISL-TP in PBMC</title>
          <description>Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>hr*pmol/10^6 cells</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5200" lower_limit="3670" upper_limit="7370"/>
                    <measurement group_id="O2" value="3780" lower_limit="2720" upper_limit="5230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>1.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of ISL-TP in PBMC</title>
        <description>Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of ISL-TP in PBMC</title>
          <description>Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>pmol/10^6 cells</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="15.1" upper_limit="27.4"/>
                    <measurement group_id="O2" value="21.6" lower_limit="13.7" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of ISL-TP in PBMC</title>
        <description>Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The Tmax of ISL-TP was expressed as a median.</description>
        <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of ISL-TP in PBMC</title>
          <description>Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The Tmax of ISL-TP was expressed as a median.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.00" lower_limit="24.00" upper_limit="240.12"/>
                    <measurement group_id="O2" value="24.00" lower_limit="4.00" upper_limit="239.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC</title>
        <description>Participants were treated with ISL and peripheral blood samples were collected at 24 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC</title>
          <description>Participants were treated with ISL and peripheral blood samples were collected at 24 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>pmol/10^6 cells</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="14.2" upper_limit="23.8"/>
                    <measurement group_id="O2" value="19.0" lower_limit="12.9" upper_limit="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>0.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC</title>
        <description>Participants were treated with ISL and peripheral blood samples were collected at 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations. One sample was missing for a Healthy participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC</title>
          <description>Participants were treated with ISL and peripheral blood samples were collected at 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations. One sample was missing for a Healthy participant.</population>
          <units>pmol/10^6 cells</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.06" lower_limit="4.69" upper_limit="13.9"/>
                    <measurement group_id="O2" value="4.43" lower_limit="0.938" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>1.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>6.02</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC</title>
        <description>Participants were treated with ISL and peripheral blood samples were collected at 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
        <time_frame>672 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC</title>
          <description>Participants were treated with ISL and peripheral blood samples were collected at 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>pmol/10^6 cells</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" lower_limit="0.982" upper_limit="3.92"/>
                    <measurement group_id="O2" value="0.730" lower_limit="0.489" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>2.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>4.80</ci_upper_limit>
            <estimate_desc>Severe Renal Impairment / Healthy</estimate_desc>
            <other_analysis_desc>GMR calculated using the mean square error referencing a t-distribution. Confidence limits exponentiated to obtain the 90% confidence interval.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2 of ISL-TP in PBMC</title>
        <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The t1/2 of plasma ISL was expressed as a geometric mean. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.</description>
        <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of ISL-TP in PBMC</title>
          <description>Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The t1/2 of plasma ISL was expressed as a geometric mean. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of important protocol deviations.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" spread="48.4"/>
                    <measurement group_id="O2" value="131" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Adverse Event (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
        <time_frame>Up to Day 29</time_frame>
        <population>All participants who received at least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Adverse Event (AE)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
          <population>All participants who received at least one dose of treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Discontinued From the Study Due to an AE</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
        <time_frame>Up to Day 29</time_frame>
        <population>All participants who received at least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued From the Study Due to an AE</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
          <population>All participants who received at least one dose of treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) from day of treatment (Day 1) up to day 29. All-cause mortality from day of randomization (Day 1) up to day 29.</time_frame>
      <desc>For AEs the population analyzed consisted of all participants who received at least one dose of treatment. For All-cause mortality the population analyzed consisted of all randomized participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Severe Renal Impairment</title>
          <description>Participants with severe renal impairment received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
        </group>
        <group group_id="E2">
          <title>Healthy</title>
          <description>Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

